Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in.

Business Wire • Dec 1, 2025

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Omeros Corporation ( OMER ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Gregory Demopulos - Co-Founder, Chairman, CEO & President David Borges - VP of Finance, Chief Accounting Officer & Treasurer Nadia Dac - VP & Chief Commercial Officer Conference Call Participants Jennifer Williams Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Stephen Brozak - WBB Securities, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation.

Seeking Alpha • Nov 17, 2025

Omeros Corporation Reports Third Quarter 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the third quarter of 2025 was $30.9 million, or $0.47 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024. For the nine months ended September 30, 2025, our net loss was $89.8 million, or $1.47 per share, compared to a net loss of $12.

Business Wire • Nov 13, 2025

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the c.

Business Wire • Nov 11, 2025

Breakout Momentum Plays You Need to Know About

Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joining a rally that has room to continue is powerful.

MarketBeat • Oct 23, 2025

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglobinuria with a differentiated mechanism, offering potential safety and dosing advantages over existing complement inhibitors. Recent phase 2 data showed significant improvements in hemoglobin and LDH levels, supporting advancement into phase 3 trials for PNH and other rare blood/kidney disorders.

Seeking Alpha • Oct 17, 2025

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?

Shares of Omeros (OMER 153.90%) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.

The Motley Fool • Oct 16, 2025

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of.

Business Wire • Oct 16, 2025

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

Zacks Investment Research • Oct 16, 2025

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to diversify beyond semaglutide amid recent headwinds.

Seeking Alpha • Oct 16, 2025